CM-313
- Generic Name
- CM-313
A Single-center Study of CM313 in Patients With Pemphigus
- Conditions
- Pemphigus
- Interventions
- Biological: glucocorticoids
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Sichuan Provincial People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06904040
- Locations
- 🇨🇳
Sichuan Provincial People's Hospital, Chengdu, China
Study of CM313 in Subject With IgA Nephropathy
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 75
- Registration Number
- NCT06830395
Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 125
- Registration Number
- NCT06791824
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 150
- Registration Number
- NCT06791772
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
- Conditions
- Platelet Transfusion Refractoriness
- Interventions
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 125
- Registration Number
- NCT06792019
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Other: placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 62
- Registration Number
- NCT06594146
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Study of CM313 in Healthy Subjects
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 51
- Registration Number
- NCT06285227
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, China
A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
- Conditions
- Immune ThrombocytopeniaTreatment
- Interventions
- Drug: Placebo Injection
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 45
- Registration Number
- NCT06199089
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2025-02-24
- Target Recruit Count
- 22
- Registration Number
- NCT05694767
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
- Conditions
- Multiple MyelomaLymphoma
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 87
- Registration Number
- NCT04818372
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital, Capital Medical University (West Branch), Beijing, Beijing, China
🇨🇳Beijing Chao-Yang Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.